HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tove Henriksen Selected Research

Apomorphine

6/2021Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation.
1/2021Close relationships in Parkinson´s disease patients with device-aided therapy.
1/2021Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
1/2019EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
1/2018Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
12/2016Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
12/2016Practical management of adverse events related to apomorphine therapy.
9/2015Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
4/2015EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
1/2014Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tove Henriksen Research Topics

Disease

17Parkinson Disease (Parkinson's Disease)
03/2022 - 01/2011
4Dyskinesias (Dyskinesia)
01/2018 - 01/2014
2Dystonia (Limb Dystonia)
11/2018 - 09/2015
1Tardive Dyskinesia
11/2018
1Glycogen Storage Disease Type VI (Glycogenosis Type VI)
12/2016
1Disruptive, Impulse Control, and Conduct Disorders (Kleptomania)
06/2015
1Pain (Aches)
06/2015
1Anhedonia
06/2015
1Hyperhidrosis
01/2011
1Hallucinations (Hallucination)
01/2011
1Nocturia
01/2011
1Illusions (Auditory Illusions)
01/2011
1Fatigue
01/2011

Drug/Important Bio-Agent (IBA)

11ApomorphineFDA Link
06/2021 - 01/2011
6Levodopa (L Dopa)FDA LinkGeneric
01/2021 - 01/2014
3Pharmaceutical PreparationsIBA
11/2018 - 05/2016
1Carbidopa (Lodosyn)FDA LinkGeneric
01/2021
1Antipsychotic Agents (Antipsychotics)IBA
11/2018
1amsonic acid (DAS)IBA
06/2015
1ropinirole (Requip)FDA LinkGeneric
06/2015
1CabergolineFDA LinkGeneric
06/2015
1Pramipexole (Mirapex)FDA LinkGeneric
06/2015
1Dopamine Agonists (Dopamine Agonist)IBA
06/2015

Therapy/Procedure

11Therapeutics
03/2022 - 01/2011
2Subcutaneous Infusions
01/2018 - 01/2011
1Drug Therapy (Chemotherapy)
01/2021
1Deep Brain Stimulation
01/2021
1Wearable Electronic Devices
01/2018
1Injections
12/2016